Alnylam Pharmaceuticals, Inc. $ALNY Shares Bought by Lansforsakringar Fondforvaltning AB publ

Lansforsakringar Fondforvaltning AB publ raised its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 5.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 42,404 shares of the biopharmaceutical company’s stock after acquiring an additional 2,173 shares during the period. Lansforsakringar Fondforvaltning AB publ’s holdings in Alnylam Pharmaceuticals were worth $19,336,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the stock. Rossby Financial LCC increased its holdings in Alnylam Pharmaceuticals by 128.6% in the 3rd quarter. Rossby Financial LCC now owns 112 shares of the biopharmaceutical company’s stock valued at $52,000 after purchasing an additional 63 shares during the last quarter. Tredje AP fonden boosted its position in shares of Alnylam Pharmaceuticals by 10.3% during the third quarter. Tredje AP fonden now owns 13,456 shares of the biopharmaceutical company’s stock worth $6,136,000 after buying an additional 1,254 shares during the period. Stevens Capital Management LP purchased a new position in shares of Alnylam Pharmaceuticals during the third quarter worth $258,000. Raiffeisen Bank International AG raised its holdings in shares of Alnylam Pharmaceuticals by 30.4% in the 3rd quarter. Raiffeisen Bank International AG now owns 11,609 shares of the biopharmaceutical company’s stock valued at $5,195,000 after buying an additional 2,705 shares during the period. Finally, Persistent Asset Partners Ltd purchased a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at $1,027,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Company reported ~ $3.0B in 2025 revenue (≈81% YoY) with Q4 net product revenue of $995M and a 151% surge in the TTR franchise — evidence of accelerating commercial momentum that supports longer‑term growth expectations. Alnylam Pharmaceuticals (ALNY) Reports $3B 2025 Revenue Driven by 151% TTR Franchise Surge
• Positive Sentiment: Canaccord Genuity raised its price target to $429, signaling stronger upside in analysts’ models and providing support for the stock’s valuation case. Canaccord Genuity Group Increases Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $429.00
• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating, and Freedom Capital upgraded ALNY to “Strong Buy” (reported via Zacks), adding buy‑side endorsement that could attract momentum investors. HC Wainwright Reaffirms “Buy” Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) Freedom Capital Upgrade via Zacks
• Neutral Sentiment: Some analysts trimmed targets after the latest reports while still expressing confidence in 2026 growth — a mixed read that leaves upside intact but tempers near‑term estimates. Analysts Trim Alnylam Pharmaceuticals, Inc. (ALNY) Targets but Keep Faith in 2026 Growth
• Neutral Sentiment: Independent valuation pieces highlight a divergence between recent share‑price performance and bullish fair‑value models — useful context for investors debating entry points. Assessing Alnylam Pharmaceuticals (ALNY) Valuation As Mixed Share Price Returns Meet Bullish Fair Value Models
• Negative Sentiment: Insider selling picked up this week: an EVP sold ~$607,447 of stock, and two other officers (Kevin Joseph Fitzgerald and Pushkal Garg) sold shares (2,041 and 2,242 shares respectively). Insider sales can create short‑term sentiment pressure even if they are routine. Insider Selling: Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $607,446.72 in Stock Kevin Joseph Fitzgerald Sells 2,041 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Pushkal Garg Sells 2,242 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

Analyst Upgrades and Downgrades

A number of brokerages recently commented on ALNY. Royal Bank Of Canada lowered their target price on Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating for the company in a report on Tuesday, January 20th. Bank of America reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 12th. HC Wainwright restated a “buy” rating and issued a $510.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday, February 18th. Raymond James Financial reiterated an “outperform” rating and set a $472.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, January 12th. Finally, Weiss Ratings raised shares of Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Thursday, January 15th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $477.96.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Jeffrey V. Poulton sold 2,242 shares of the firm’s stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $310.08, for a total transaction of $695,199.36. Following the sale, the executive vice president owned 59,802 shares of the company’s stock, valued at approximately $18,543,404.16. This trade represents a 3.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Tolga Tanguler sold 1,959 shares of the business’s stock in a transaction that occurred on Friday, February 13th. The stock was sold at an average price of $310.08, for a total transaction of $607,446.72. Following the sale, the executive vice president owned 31,769 shares of the company’s stock, valued at $9,850,931.52. This represents a 5.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 36,578 shares of company stock worth $12,416,105. 1.20% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Trading Down 0.9%

NASDAQ ALNY opened at $336.19 on Monday. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $495.55. The firm has a 50 day moving average of $366.89 and a two-hundred day moving average of $422.43. The company has a quick ratio of 2.71, a current ratio of 2.76 and a debt-to-equity ratio of 1.28. The stock has a market capitalization of $44.59 billion, a PE ratio of 196.60 and a beta of 0.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.43 by ($0.61). The firm had revenue of $1.10 billion for the quarter, compared to analysts’ expectations of $1.16 billion. Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.Alnylam Pharmaceuticals’s revenue for the quarter was up 84.9% on a year-over-year basis. During the same period last year, the firm posted ($0.65) earnings per share. As a group, research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.